Movement Alert｜Natera Overnight Rise 13.05%, Q2 Revenue Beats Estimates by 14% and Full-Year Guidance Raised

Market Focus08-07

On August 7, Natera rose 13.05% overnight, trading at $300.01/share. The surge was driven by the company's Q2 earnings report that significantly exceeded market expectations on both top and bottom lines, accompanied by an upward revision of full-year revenue guidance.

Natera reported Q2 revenue of $752.8 million, up 37.7% year-over-year, substantially surpassing the analyst consensus estimate of approximately $661 million. Adjusted loss per share narrowed to $0.47, improving 36.5% from a loss of $0.74 in the year-ago quarter and beating the Street estimate of $0.49. The company simultaneously raised its full-year revenue guidance to $2.85 billion-$2.91 billion, above its prior forecast of $2.74 billion-$2.82 billion and the FactSet consensus of $2.80 billion.

The strong results come amid a series of positive catalysts for Natera's core Signatera MRD test, including EU IVDR Class C certification, Japan PMDA clearance for colorectal cancer, NCCN Category 1 recommendation in bladder cancer, and multiple phase 3 clinical partnerships with Aveta Biomics and Eledon Pharmaceuticals, reinforcing its leadership position in molecular residual disease testing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121095014?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 08:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121095014","market":"us","top_or_hot":-1,"title":"Movement Alert｜Natera Overnight Rise 13.05%, Q2 Revenue Beats Estimates by 14% and Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On August 7, Natera rose 13.05% overnight, trading at $300.01/share. The surge was driven by the company's Q2 earnings report that significantly exceeded market expectations on both top and bottom lines, accompanied by an upward revision of full-year revenue guidance.</p><p>Natera reported Q2 revenue of $752.8 million, up 37.7% year-over-year, substantially surpassing the analyst consensus estimate of approximately $661 million. Adjusted loss per share narrowed to $0.47, improving 36.5% from a loss of $0.74 in the year-ago quarter and beating the Street estimate of $0.49. The company simultaneously raised its full-year revenue guidance to $2.85 billion-$2.91 billion, above its prior forecast of $2.74 billion-$2.82 billion and the FactSet consensus of $2.80 billion.</p><p>The strong results come amid a series of positive catalysts for Natera's core Signatera MRD test, including EU IVDR Class C certification, Japan PMDA clearance for colorectal cancer, NCCN Category 1 recommendation in bladder cancer, and multiple phase 3 clinical partnerships with Aveta Biomics and Eledon Pharmaceuticals, reinforcing its leadership position in molecular residual disease testing.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Natera Overnight Rise 13.05%, Q2 Revenue Beats Estimates by 14% and Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Natera Overnight Rise 13.05%, Q2 Revenue Beats Estimates by 14% and Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 08:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, Natera rose 13.05% overnight, trading at $300.01/share. The surge was driven by the company's Q2 earnings report that significantly exceeded market expectations on both top and bottom lines, accompanied by an upward revision of full-year revenue guidance.</p><p>Natera reported Q2 revenue of $752.8 million, up 37.7% year-over-year, substantially surpassing the analyst consensus estimate of approximately $661 million. Adjusted loss per share narrowed to $0.47, improving 36.5% from a loss of $0.74 in the year-ago quarter and beating the Street estimate of $0.49. The company simultaneously raised its full-year revenue guidance to $2.85 billion-$2.91 billion, above its prior forecast of $2.74 billion-$2.82 billion and the FactSet consensus of $2.80 billion.</p><p>The strong results come amid a series of positive catalysts for Natera's core Signatera MRD test, including EU IVDR Class C certification, Japan PMDA clearance for colorectal cancer, NCCN Category 1 recommendation in bladder cancer, and multiple phase 3 clinical partnerships with Aveta Biomics and Eledon Pharmaceuticals, reinforcing its leadership position in molecular residual disease testing.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"","article_id":"1121095014","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121095014","pubTimestamp":1786061745,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, Natera rose 13.05% overnight, trading at $300.01/share. The surge was driven by the company's Q2 earnings report that significantly exceeded market expectations on both top and bottom...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc."},"translate_title":"走势警报|Natera 隔夜上涨 13.05%，第二季度收入超出预期 14%，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1},"content_text":"On August 7, Natera rose 13.05% overnight, trading at $300.01/share. The surge was driven by the company's Q2 earnings report that significantly exceeded market expectations on both top and bottom lines, accompanied by an upward revision of full-year revenue guidance.Natera reported Q2 revenue of $752.8 million, up 37.7% year-over-year, substantially surpassing the analyst consensus estimate of approximately $661 million. Adjusted loss per share narrowed to $0.47, improving 36.5% from a loss of $0.74 in the year-ago quarter and beating the Street estimate of $0.49. The company simultaneously raised its full-year revenue guidance to $2.85 billion-$2.91 billion, above its prior forecast of $2.74 billion-$2.82 billion and the FactSet consensus of $2.80 billion.The strong results come amid a series of positive catalysts for Natera's core Signatera MRD test, including EU IVDR Class C certification, Japan PMDA clearance for colorectal cancer, NCCN Category 1 recommendation in bladder cancer, and multiple phase 3 clinical partnerships with Aveta Biomics and Eledon Pharmaceuticals, reinforcing its leadership position in molecular residual disease testing.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121095014","isCrawlerRequest":true}